The investigational HER2-selective tyrosine kinase inhibitor zongertinib appears remarkably effective in patients with HER2-mutant non–small cell lung cancer. Robust, durable responses were seen in ...

According to data announced today at the American Association for Cancer Research Annual Meeting 2025, Merck’s anti-PD-1 mAb pembrolizumab (Keytruda) led to significant improvements in event-free ...

1Department of Pathology, Stanford University School of Medicine, Stanford, California.

Renowned scientist Douglas Hanahan, PhD, discusses the legacy of The Hallmarks of Cancer, the challenge of adaptive resistance, and how insights into the tumor microenvironment and cancer neuroscience ...

Daniel Drucker, a pioneer in GLP-1 receptor–agonist research, discusses the history of the drugs, their wide-ranging benefits, and how they might benefit patients with cancer. On April 28, 2005, the ...

St. Jude Children's Research Hospital, Memphis, TN.

Search for other works by this author on: ...

Voronoi, Inc., incheon, Republic of Korea.

A high-resolution map of how protein organization inside the cell provides a platform for interrogating the way cancer mutations disrupt entire protein assemblies—not just individual genes. By ...

The Chinese company Akeso Biopharma’s PD-1 inhibitor penpulimab was approved by the FDA— when given in combination with chemotherapy—to treat patients with recurrent or metastatic non-keratinizing ...

Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia. *Corresponding Author: Priti Bandi, Risk Factors and Screening Research, Surveillance and Health Equity Science, ...

W. Kimryn Rathmell, MD, PhD, has accepted the role as CEO of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. She was ...